HDM 1005
Alternative Names: HDM-1005Latest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator Hangzhou Zhongmei Huadong Pharmaceutical
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 26 Sep 2024 Hangzhou Zhongmei Huadong Pharmaceutical completes a phase-Ia clinical trial in Obesity (In volunteers) in China (SC) (NCT06640647) (CTR20240892)
- 18 Sep 2024 Preclinical trials in Obesity in China (SC) prior to September 2024
- 18 Sep 2024 Preclinical trials in Type 2 diabetes mellitus in China (SC) prior to September 2024